Ion exchange (IEX) chromatography is a commonly used purification method that separates a target molecule from other impurities based on the net surface charge. Our portfolio of anion exchange (AEX) and cation exchange (CEX) resins, with our multi-modal chromatography resins, offers efficient purification solutions for mAbs, vaccines, plasmid DNA, plasma, and other modalities.
These resins are ideal for efficient downstream purification and contain our proven tentacle ligand technology coupled with rigid base beads. They operate at fast flowrates and maintain high binding capacities, improving productivity by reducing time and manufacturing costs.
Eshmuno® CMX mixed-mode resin provides high selectivity for mAbs, fusion proteins, and ADC purification, as well as separation of low molecular weight impurities and HCPs.
Eshmuno® CP-FT resin efficiently removes mAb aggregates in flow-through mode, resulting in 10 times higher loading capacities as compared to traditional bind/elute CEX chromatography. This enables process intensification while reducing the overall cost for downstream mAb purification.
Eshmuno® CPS resin offers high dynamic binding capacity and separation efficiency of recombinant protein feed streams at elevated salt concentrations. This enables direct loading of high-conductivity feed streams (conductivity ≥10 mS/cm), reducing the need for dilution.
Eshmuno® CPX resin separates mAb monomers from aggregates and other impurities, even at high loading. It delivers outstanding productivity for high-resolution purification of process intermediates.
Eshmuno® HCX resin provides fast, efficient, direct capture of proteins, delivering outstanding performance in typical ion exchange and flow-through applications at higher salt levels.
Eshmuno® S is a strong CEX resin for direct capture of recombinant proteins and fast, efficient mAb purification following protein A capture.
Eshmuno® Q is a strong anion resin, offering outstanding impurity removal in typical anion exchange flow-through applications.
All Fractogel® EMD resins provide high selectivity coupled with consistent pressure stability, enabling very high throughput and excellent yields. The resin’s high binding capacity, even at high flow rates, saves valuable time and improves process economics. Fractogel® resins are offered in different bead sizes with multiple functional groups to meet a range of purification needs:
Complementing our product portfolio, the Emprove® Program provides three types of dossiers to support different stages of development and manufacturing operations such as qualification, risk assessment, and process optimization. The dossiers consolidate comprehensive product-specific testing data, quality statements, and regulatory information in a readily available format to simplify your compliance needs.
Bulk Resin, Membranes and Prepacked Columns
Protein A Affinity Chromatography Options
A highly selective mixed mode chromatography resin for difficult to purify mAbs, ADCs and fusion proteins
A cation exchange resin specifically developed for the flow-through removal of aggregates using frontal chromatography
High capacity and salt tolerance for recombinant protein purification
Efficient impurity removal and strong binding capacity at high flow rates
New, high salt-tolerant multi-mode chromatography resin
For superior downstream mAB purification
Eshmuno® Q resin is a strong anion exchange (AEX) resin, coupling our renowned tentacle structure with a hydrophilic polyvinyl ether base matrix
Fractogel® resins consist of synthetic methacrylate based polymeric beads providing excellent pressure stability resulting in high flow rates
Small-scale prepacked chromatography columns for rapid process development, method optimization, parameter screening and sample preparation
A highly selective mixed mode chromatography resin for difficult to purify mAbs, ADCs and fusion proteins.
The mAbsizer™ Calculator estimates the quantity of MilliporeSigma products required to express, purify, and formulate a mAb effectively.
Manufacturers strive toward cost-effective purification of target molecules and a high level of confidence that their biologics are safe and not compromised by the presence of endogenous retrovirus-like particles or adventitious viruses.
This article reviews the current dynamics in the RNA therapeutics/vaccines market as well as differences between small-interfering RNA (siRNA), RNA interference (RNAi), microRNA (miRNA), and messenger RNA (MRNA).
New Technologies Are Emerging to Overcome Challenges Associated with Toxicity and Drug Delivery.
The aim of this technical note is to provide a description of the steps followed and considerations taken during the development of antibody drug conjugate separation using a mixed mode cation exchange chromatography step.
The bioprocessing industry is interested in Next Generation Processes with higher flexibility, lower costs, and higher product quality.
The aim of this technical note is to provide a description of the capture and subsequent purification of glycoproteins.
The aim of this technical note is to provide a description of the steps followed and considerations taken during the development of a CEX chromatography step in a mAb process.
To continue reading please sign in or create an account.
Don't Have An Account?